Items in AFP with MESH term: Anti-HIV Agents

Pages: Previous 1 2 3

Clinical Briefs - Clinical Briefs


Acute HIV-1 Infection: Early Identification and Treatment - Editorials


Clinical Briefs - Clinical Briefs


Significant FDA Approvals in 1999 - FDA Perspective


HHS Updates Guidelines for Antiretroviral Therapy in HIV Infection - Practice Guidelines


Clinical Briefs - Clinical Briefs


Antiretroviral Therapy to Prevent Transmission in HIV-Discordant Couples - Cochrane for Clinicians


Antiretroviral Preexposure Prophylaxis for Preventing HIV Infection in High-Risk Individuals - Cochrane for Clinicians


Corticosteroids for Presumed Pneumocystis Pneumonia in Patients with HIV Infection - FPIN's Clinical Inquiries


What Is New in HIV Infection? - Article

ABSTRACT: Human immunodeficiency virus (HIV) prevention and treatment updates include screening recommendations, fourth-generation testing, preexposure prophylaxis, and a paradigm shift; treatment is prevention. The U.S. Preventive Services Task Force recommends routine HIV screening in persons 15 to 65 years of age, regardless of risk. Fourth-generation testing is replacing the Western blot and can identify those with acute HIV infection. The U.S. Food and Drug Administration approved the OraQuick In-Home HIV Test; however, there are concerns about reduced sensitivity, possible misinterpretation of results, potential for less effective counseling, and possible cost barriers. Preexposure prophylaxis (effective in select high-risk adult populations) is the combination of safer sex practices and continuous primary care prevention services, plus combination antiretroviral therapy. Concerns for preexposure prophylaxis include the necessity of strict medication adherence, limited use among high-risk populations, and community misconceptions of appropriate use. Evidence supports combination antiretroviral therapy as prevention for acute HIV infection, thus lowering community viral loads. Evidence has increased supporting combination antiretroviral therapy for treatment at any CD4 cell count. Resistance testing should guide therapy in all patients on entry into care. Within two weeks of diagnosis of most opportunistic infections, combination antiretroviral therapy should be started; patients with tuberculosis and cryptococcal meningitis require special considerations.


Pages: Previous 1 2 3


Information From Industry